Table 2.
This table gives a detailed overview of the performance of the nomograms (discrimination = c-Index, and calibration = interpretation of the calibration plot) on development and validation studies.
| INFORMATION | Abdul-Muhsin H | Cha EK | Chen J | Chen X | Fang D | Hou G | Jeldres C | Kim M | Kim S | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | 2012 | 2021 | 2020 | 2020 | 2020 | 2010 | 2015 | 2019 | ||||||||||||||
| OUTCOME / GROUP | Overall survival | Cancer Specific Survival | Metasatasis Free Survival | Cancer Specific Surival | Recurrence Free Survival | Overall Survival | Overall Survival | Overall Survival | Cancer Specific Survival | Cancer Specific Survival | Cancer Specific Survival | Recurrence Free Survival | Recurrence Free Survival | |||||||||
| A | B1 | C | B1, B3 | C | A | A | A | E | B1, B2 | B1, B2 | C | C | ||||||||||
| RESULTS | c-Index Development Paper¹ | 0.784 | 0.714 | 0.753 | 0.815 | 0.768 | 0,804 (95%CI 0,713-0,895) | 0.82 | 0,698 0,724 | NI | 0,753 | 0,802 (95%CI 0,752-0,851) | 0,788 (95%CI 0,73-0,826) | 0,657 (95%CI 0,560-0,755) | ||||||||
| c-Index External Validation | NI | NI | NI | 0,69 0,7 | NI | NI | NI | NI | NI | NI | NI | NI | NI | |||||||||
| Calibration Plot Development Paper Interpretation Authors 3 years / 5 years (+/~/-)1,2 | NI / + | NI / + | NI / + | NI / + | NI / + | NI / + | + / + | ~ / NI | + / + | NI / + | NI / + | NI / + | + / NI | |||||||||
| Calibration Plot External Validation Interpretation Authors 3 years / 5 years (+/~/-)² | NI | NI | NI | NI / NI | NI | NI | NI | NI | NI | NI | NI | NI | NI | |||||||||
| INFORMATION | Krabbe LM | Lai S 2 | Roupret M | Seisen T | Wang M | Xylinas E | Yates DR | Zeng S | Zhang G | Zhang X | ||||||||||||
| 2017 | 2021 | 2013 | 2014 | 2021 | 2014 | 2012 | 2019 | 2019 | 2020 | |||||||||||||
| OUTCOME / GROUP | Recurrence Free Survival | Intravesical Recurrence | Cancer Specific Survival | Cancer Specific Survival | HG Group Overall Survival | LG Group Overall Survival | Intravesical Recurrence Full Model | Intravesical Recurrence Reduced Modell | Cancer Specific Survival | Cancer Specific Survival | Overall Survival | Cancer Specific Survival | No Intravesical Recurrence | |||||||||
| C | D | B1, B3 | B1, B2 | A | A | D | D | B1, B2 | B1, B3 | A | B1 | D | ||||||||||
| RESULTS | c-Index Development Paper¹ | 0,76 (±0,012) | NI | 0,79 (95% CI 0,75-0,83) | 0,8 (95%CI 0,76-0,84) | 0,729 (95%CI 0,707-0,750) 0,763 (95% CI 0,656-0,869) | 0,731 (95%CI 0,67-0,791) 0,825 (95%CI 0,648-1) | 0.69 | 0.678 | 0.78 | 0,73 (95%CI 0,59-0,87) | 0,702 (95%CI 0,684-0,720) | 0,771 (95%CI 0,746-0,796) | 0,678 (95%CI 0,583-0,772) | ||||||||
| c-Index External Validation | NI | NI | NI | NI | NI | NI | 0.684 | 0.683 | 0.742 | NI | NI | NI | NI | |||||||||
| Calibration Plot Development Paper Interpretation Authors 3 years / 5 years (+/~/-)1,2 | NI / ~ | + / NI + / NI | NI / ~ | NI / + | + / + | + / + | + / NI | + / NI | + / - | ~ / ~ | + / + | + / + | + / NI | |||||||||
| Calibration Plot External Validation Interpretation Authors 3 years / 5 years (+/~/-)² | NI | NI | NI | NI | NI | NI | + / NI + / NI | + / NI | - / - | NI | NI | NI | NI | |||||||||
¹We only report the c-Index/calibration plot accounting best for overfitting (split cohort validation > bootstrapping/resample validation > development cohort).
²If calibration plot was given but without interpretation from the authors, the reviewers interpreted the calibration plot. NI, no information given.